- Stocks
- Healthcare
- NASDAQ: AMGN

Price (delayed)

$333.99

Market cap

$179.16B

P/E Ratio

47.44

Dividend/share

$8.76

EPS

$7.04

Enterprise value

$233.48B

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. One of the world's largest independent biotechnology companies, Amgen was established in Thousand Oaks, California, in 1980.

The revenue has grown by 13% year-on-year and by 4.8% since the previous quarter

The P/E is 129% above the 5-year quarterly average of 20.7 and 95% above the last 4 quarters average of 24.3

AMGN's quick ratio has dropped by 68% year-on-year and by 15% since the previous quarter

What are the main financial stats of AMGN

Market
Valuations
Earnings

Shares outstanding

536.43M

Market cap

$179.16B

Enterprise value

$233.48B

Price to earnings (P/E)

47.44

Price to book (P/B)

35.64

Price to sales (P/S)

6.06

EV/EBIT

31.13

EV/EBITDA

19.34

EV/Sales

7.91

Revenue

$29.53B

EBIT

$7.5B

EBITDA

$12.07B

Free cash flow

$7.1B

Per share
Balance sheet
Liquidity

EPS

$7.04

Free cash flow per share

$13.24

Book value per share

$9.37

Revenue per share

$55.1

TBVPS

$80.29

Total assets

$92.98B

Total liabilities

$87.96B

Debt

$64.02B

Equity

$5.02B

Working capital

$8.32B

Debt to equity

12.75

Current ratio

1.42

Quick ratio

0.84

Net debt/EBITDA

4.5

Margins
Efficiency
Dividend

EBITDA margin

40.9%

Gross margin

66.4%

Net margin

12.7%

Operating margin

23.6%

Return on assets

4.1%

Return on equity

58.6%

Return on invested capital

10%

Return on capital employed

10.2%

Return on sales

25.4%

Dividend yield

2.62%

DPS

$8.76

Payout ratio

124.4%

How has the Amgen stock price performed over time

Intraday

-0.46%

1 week

-0.26%

1 month

7.47%

1 year

44.95%

YTD

15.96%

QTD

6.89%

How have Amgen's revenue and profit performed over time

Revenue

$29.53B

Gross profit

$19.6B

Operating income

$6.97B

Net income

$3.76B

Gross margin

66.4%

Net margin

12.7%

The net margin has dropped by 58% year-on-year and by 47% since the previous quarter

The net income has plunged by 52% YoY and by 44% from the previous quarter

The company's operating margin fell by 31% YoY and by 16% QoQ

AMGN's operating income is down by 22% year-on-year and by 12% since the previous quarter

What is Amgen's growth rate over time

What is Amgen stock price valuation

P/E

47.44

P/B

35.64

P/S

6.06

EV/EBIT

31.13

EV/EBITDA

19.34

EV/Sales

7.91

The P/E is 129% above the 5-year quarterly average of 20.7 and 95% above the last 4 quarters average of 24.3

AMGN's EPS has dropped by 52% year-on-year and by 44% since the previous quarter

The stock's price to book (P/B) is 56% more than its last 4 quarters average of 22.8 and 27% more than its 5-year quarterly average of 28.0

Amgen's equity has decreased by 19% from the previous quarter and by 6% YoY

The P/S is 19% more than the last 4 quarters average of 5.1 and 17% more than the 5-year quarterly average of 5.2

The revenue has grown by 13% year-on-year and by 4.8% since the previous quarter

How efficient is Amgen business performance

The ROE has plunged by 72% YoY and by 43% from the previous quarter

AMGN's return on assets has dropped by 64% year-on-year and by 44% since the previous quarter

The ROIC has contracted by 48% YoY and by 31% from the previous quarter

AMGN's return on sales is down by 38% year-on-year and by 33% since the previous quarter

What is AMGN's dividend history

DPS

$8.76

Dividend yield

2.62%

Payout ratio

124.4%

Recent dividends

How did Amgen financials performed over time

Amgen's total assets is 6% more than its total liabilities

AMGN's quick ratio has dropped by 68% year-on-year and by 15% since the previous quarter

Amgen's current ratio has plunged by 55% YoY and by 14% from the previous quarter

AMGN's debt to equity is up by 23% QoQ and by 11% YoY

Amgen's equity has decreased by 19% from the previous quarter and by 6% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.